It has been almost 40 years since the first biologic drug reached the market. That drug was human insulin, which was produced by cloning human genes into E. coli for protein expression at a scale suitable for therapeutic use. Today, biologics are expected to be the fastest-growing segment of the pharmaceutical industry, reaching a predicted worth of $1.2 trillion by 2030.
Because biologic drugs are produced in living systems, it is critical that they are separated from potentially harmful contaminants or impurities such as host cell proteins, cell debris, and any other impurities before being dosed in man. However, established purification techniques employ lengthy protocols and often incur substantial product losses, leading many biologics manufacturers to seek a more viable alternative.
In this white paper you will learn more on:
- The benefits of affinity chromatography for the purification of novel biologics
- How the CaptureSelect™ technology supports biotherapeutic development
- Real case studies demonstrating the use of CaptureSelect™ affinity chromatography